Kisqali
Term · Oncology and biomedicine · MLC-T-ONC-004650
A drug used with an aromatase inhibitor or fulvestrant (a type of hormone therapy) to treat adults with certain types of hormone-receptor positive, HER2-negative breast cancer. It is also being studied in the treatment of other types of cancer. Kisqali blocks certain proteins, which may help keep cancer cells from growing. It is a type of cyclin-dependent kinase inhibitor. Also called ribociclib succinate.
| Identifier | MLC-T-ONC-004650 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | ribociclib succinate |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-004650",
"term": "Kisqali",
"field": "Oncology and biomedicine",
"definition": "A drug used with an aromatase inhibitor or fulvestrant (a type of hormone therapy) to treat adults with certain types of hormone-receptor positive, HER2-negative breast cancer. It is also being studied in the treatment of other types of cancer. Kisqali blocks certain proteins, which may help keep cancer cells from growing. It is a type of cyclin-dependent kinase inhibitor. Also called ribociclib succinate.",
"synonyms": [
"ribociclib succinate"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/kisqali/"
}
Record 9,786 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.